Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples

dc.contributor.authorOlivan Riera, Mireia
dc.contributor.authorGarcia, Marta
dc.contributor.authorSuárez, Leticia
dc.contributor.authorGuiu, Marc
dc.contributor.authorGros, Laura
dc.contributor.authorMéndez, Olga
dc.contributor.authorRigau, Marina
dc.contributor.authorReventós Puigjaner, Jaume
dc.contributor.authorSegura, Miguel F.
dc.contributor.authorTorres, Inés de
dc.contributor.authorPlanas, Jacques
dc.contributor.authorCruz, Xavier de la
dc.contributor.authorGomis i Cabré, Roger
dc.contributor.authorMorote, Juan
dc.contributor.authorRodríguez Barrueco, Ruth
dc.contributor.authorSantamaria Margalef, Anna
dc.date.accessioned2022-01-13T18:50:09Z
dc.date.available2022-01-13T18:50:09Z
dc.date.issued2021-12-09
dc.date.updated2022-01-13T13:08:14Z
dc.description.abstractAbout 70% of advanced-stage prostate cancer (PCa) patients will experience bone metastasis, which severely affects patients' quality of life and progresses to lethal PCa in most cases. Hence, understanding the molecular heterogeneity of PCa cell populations and the signaling pathways associated with bone tropism is crucial. For this purpose, we generated an animal model with high penetrance to metastasize to bone using an intracardiac percutaneous injection of PC3 cells to identify PCa metastasis-promoting factors. Using genomic high-throughput analysis we identified a miRNA signature involved in bone metastasis that also presents potential as a biomarker of PCa progression in human samples. In particular, the downregulation of miR-135b favored the incidence of bone metastases by significantly increasing PCa cells' migratory capacity. Moreover, the PLAG1, JAKMIP2, PDGFA, and VTI1b target genes were identified as potential mediators of miR-135b's role in the dissemination to bone. In this study, we provide a genomic signature involved in PCa bone growth, contributing to a better understanding of the mechanisms responsible for this process. In the future, our results could ultimately translate into promising new therapeutic targets for the treatment of lethal PCa.
dc.format.extent22 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec717929
dc.identifier.pmid34944822
dc.identifier.urihttps://hdl.handle.net/2445/182321
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers13246202
dc.relation.ispartofCancers, 2021, vol. 13, num. 24, p. 6202
dc.relation.urihttps://doi.org/10.3390/cancers13246202
dc.rightscc by (c) Olivan Riera, Mireia et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationCàncer de pròstata
dc.subject.classificationMetàstasi
dc.subject.classificationMarcadors bioquímics
dc.subject.otherProstate cancer
dc.subject.otherMetastasis
dc.subject.otherBiochemical markers
dc.titleLoss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
cancers-13-06202.pdf
Mida:
4.66 MB
Format:
Adobe Portable Document Format